Shares of InflaRx N.V. (NASDAQ:IFRX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7.43.
Several equities research analysts recently weighed in on IFRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, September 21st. Needham & Company LLC started coverage on shares of InflaRx in a research report on Monday, September 14th. They set a “buy” rating and a $8.00 price target for the company. Cantor Fitzgerald lifted their price objective on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th.
Get Our Latest Report on InflaRx
Institutional Trading of InflaRx
A number of hedge funds and other institutional investors have recently bought and sold shares of IFRX. China Universal Asset Management Co. Ltd. raised its holdings in InflaRx by 47.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 23,600 shares of the company’s stock worth $44,000 after buying an additional 7,600 shares during the last quarter. T3 Companies LLC grew its position in shares of InflaRx by 32.9% in the third quarter. T3 Companies LLC now owns 440,000 shares of the company’s stock valued at $792,000 after purchasing an additional 108,986 shares during the period. SteelPeak Wealth LLC acquired a new position in InflaRx in the third quarter valued at approximately $419,000. AXQ Capital LP purchased a new position in InflaRx during the second quarter valued at approximately $41,000. Finally, Montanova Capital LLC lifted its stake in InflaRx by 189.1% during the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock worth $51,372,000 after purchasing an additional 15,000,000 shares during the period. Institutional investors own 42.39% of the company’s stock.
InflaRx Stock Performance
Shares of NASDAQ:IFRX opened at $1.30 on Friday. The company has a market capitalization of $192.32 million, a P/E ratio of -3.35 and a beta of 2.38. The company’s 50-day moving average is $1.79 and its 200 day moving average is $1.64. InflaRx has a fifty-two week low of $0.80 and a fifty-two week high of $2.95.
InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. As a group, research analysts predict that InflaRx will post -0.23 earnings per share for the current year.
About InflaRx
InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.
The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.
Featured Stories
- Five stocks we like better than InflaRx
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
